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Abstract 
Subtype-specific incidence patterns in populations at high-risk of lymphoma offer insight into 
lymphomagenesis. The incidence profiles for the two most common non-Hodgkin lymphoma 
subtypes were compared for two immune-deficient populations, adults receiving a kidney 
transplant 1982-2003 (n=7,730) or diagnosed with HIV infection 1982-2004 (n=17,175). 
National population-based registries were linked and standardized incidence ratios (SIRs) 
were computed for each cohort and lymphoma subtype. Risk of diffuse large B-cell 
lymphoma was significantly increased after transplantation (SIR 17.83, 95%CI 13.61-22.95) 
and after HIV infection (SIR 58.81, 95%CI 52.59-65.56). Rates of follicular lymphoma were 
neither significantly increased nor decreased in transplant recipients (SIR 0.82, 95%CI 0.10-
2.96) and in people with HIV (SIR 1.25, 95%CI 0.41-2.91). The findings argue against an 
infectious or other immune-deficiency- related aetiology for follicular lymphoma, and clearly 
differentiate it from diffuse large B-cell lymphoma. 
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Non-Hodgkin lymphoma (NHL) is an immune-deficiency associated malignancy, 
occurring at markedly increased rates in people with HIV-related, iatrogenic, and congenital 
immune deficiency.1-3 NHL includes an array of lymphoma subtypes displaying 
morphological, clinical, and prognostic heterogeneity.4 Despite this heterogeneity, consistent 
evidence of variation in etiological associations for the most common variants is limited, 
although it has been hypothesized that immune dysfunction may be more important for 
diffuse large B-cell NHL (DLBCL) than for follicular lymphoma (FL).5 A comparison of the 
lymphoma subtype-specific incidence profiles for immunodeficient populations may support 
different mechanisms for lymphomagenesis by subtype. 
Here we report population-based standardized incidence ratios (SIRs) for the two most 
common World Health Organization (WHO) 2001 NHL subtypes in national cohorts of adult 
kidney transplant recipients and adults with HIV infection. 
Material and methods 
The transplant cohort included all adults (16-80 years) receiving a kidney transplant in 
Australia 1982-2003 (n=7,730), as notified to the Australia and New Zealand Dialysis and 
Transplant Registry (ANZDATA). The ANZDATA Registry is a population-based register of 
all patients who commenced chronic dialysis or receive a kidney transplant in Australia and 
New Zealand, collected via surveys of patients’ treating dialysis or transplant units. 
The HIV cohort included all adults (16-80 years) diagnosed with HIV in Australia 
from 1982 until 2004 (n=20,232), as notified to the Australian National HIV/AIDS Registries. 
HIV infection and AIDS are separately notifiable conditions in Australia6, and nationwide 
HIV surveillance commenced in 19897. As NHL is an AIDS-defining cancer, analysis of NHL 
incidence was restricted to people with a known date of HIV diagnosis (n=17,175, 85%); 
people notified only with AIDS were excluded. 
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Incident lymphomas were ascertained using probabilistic data linkage between each 
cohort and the Australian National Cancer Statistics Clearing House (NCSCH).8, 9 This 
database records incident invasive cancers diagnosed in Australian residents since 1st January 
1982, except non-melanoma skin cancer, as notified by statute to the jurisdictional cancer 
registries. For each matched record, the date of diagnosis and the tumor topography (ICD-10) 
and morphology (ICD-O-3) codes were obtained. The classification of DLBCL and FL was 
stable over the entire period of follow-up10, and the lymphoma subtypes were classified 
according to current guidelines for epidemiological research4. 
Person-years (PY) of follow-up commenced on the date of HIV diagnosis or the date 
of kidney transplantation. PY were accrued until the date of lymphoma diagnosis, 80 years of 
age, death, or the last date of cancer registration, whichever occurred first. For kidney 
transplant recipients, PY were accrued only during periods of transplant function; time on 
dialysis after graft failure and before re-transplantation did not contribute. 
SIR with 95% exact CI were computed assuming a Poisson distribution11 and 
compared the number of observed cases in each cohort with that expected based on the 
application of five-year age-, sex-, state/territory-, and calendar-year-specific general 
population subtype-specific incidence rates. 
All analyses were performed using Stata version 10 (StataCorp LP, College Station, 
Tex). 
Approval for the use of the datasets for the purpose of data linkage was obtained from 
all relevant data custodians and institutional review boards. The need for informed consent 
was waived on account of the researchers receiving only de-identified data. 
Results 
In total, there were 50,472 PY (mean 6.5) of follow-up after transplantation and 
135,179 PY (mean 7.9) of follow-up after HIV diagnosis (Table 1). Compared to transplant 
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recipients, people with HIV infection were far more likely to be male (p<0.0001) and 
substantially younger (p<0.0001). These differences precluded a quantitative comparison of 
the subtype-specific SIRs. A total of 117 NHLs were observed in transplant recipients and 
661 in people with HIV. In both cohorts, the risk of DLBCL was significantly raised, and 
there was no significant increase or decrease in risk of FL (Table 2). As a large proportion 
(35-40%) of incident NHLs was unclassifiable in each cohort, a sensitivity analysis was 
performed and a proportionate number of NOS NHLs were counted as FL. These sensitivity 
analyses did not alter the incidence estimates for FL (SIR 1.23 (95% CI 0.25-3.59) in kidney 
transplant recipients, SIR 2.00 (95% CI 0.86-3.93) in people with HIV). 
Discussion 
This national, population-based study examined the risk of DLBL and FL in two 
immune-deficient populations using identical methods, over the same time period. We found 
that DLBCL incidence was significantly increased in both populations. The novel finding 
regarding the implications for lymphomagenesis was that in both cohorts, FL risk did not 
differ from that of the background population in either cohort. In both, immunodeficiency is 
characterized by a reduction, or depletion in function of T helper cells13, 14 and both are known 
to be at excess risk of neoplasms with an infectious cause12 . These observations argue against 
a predominant role for a known, or as yet unidentified, oncogenic infectious agent, in FL 
pathogenesis. Furthermore, as immunodeficiency in both populations is characterized by a 
reduction, or depletion in function of T helper cells13, 14, this finding suggests that the 
malignant transformation and expansion of germinal-centre derived follicular B-cells is not 
under the direct control of cellular immunity. 
Excess risk of DLBCL in people with HIV infection is well-established15 and NHL 
risk is strongly correlated with the current severity of HIV-related immunodeficiency16. 
Previous SIR data on the risk of DLBCL after transplantation is limited to a non-population-
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based cohort study of 78 histopathologically verified incident cases (1964-2007) which found 
a significant excess risk (SIR 32).17 Much of the excess risk of DLBCL in immunodeficiency 
can be attributed to the inability to mount an effective immune response against Epstein-Barr 
virus (EBV) infection or reactivation.18, 19 EBV is present in up to 80% of DLBCL in people 
with HIV2 and is also present in a sizable proportion of post-transplant lymphoproliferative 
disorders2, particularly those occurring early after transplantation20. 
Unlike DLBCL, follicular lymphoma is not a specified AIDS-defining condition, and 
involvement of EBV, or another infections oncologic agent has not been established. The risk 
of FL in people with HIV infection relative to the general population has been quantified in 
only one prior population-based study (1975-1990), for a cohort defined by a non-NHL 
related AIDS diagnosis (SIR 6.83, 95% CI 1.86-17.48).21 For transplantation, risk relative to 
the general population has been quantified in one non-population-based study (0 observed and 
0.4 expected cases; p=0.98).17 There are no published subtype-specific SIR estimates for NHL 
in other forms of immune dysregulation, including primary immune deficiency and 
autoimmune disease. However, other epidemiological evidence consistently shows stronger 
associations between autoimmune disease and DLBCL risk compared to FL risk.22, 23 
The key strength of this study is its population-base, including the cancer 
ascertainment, which minimized bias by using the same approach for the cohorts and the 
general population, and high quality cancer registration processes (Curado2007; Tracey2009). 
Accordingly however, histopathological review was not possible. A large proportion (35-
40%) of incident NHLs were unclassifiable, demonstrating the difficulty of accurate 
lymphoma diagnosis in these immunosuppressed hosts; however, the reliability of FL 
diagnosis is at least 89%.4, 10 Despite this uncertainty, sensitivity analyses did not alter the 
significance of the SIR estimate for FL for either cohort. In addition, while we restricted the 
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study to adults, the elderly are largely unrepresented in these cohorts, and thus the expected 
numbers of lymphomas were low. 
Using a large-scale, systematic approach, we quantified the site-specific NHL risk in 
two immune deficient states and found no association with FL. We believe this indicates that 
FL occurring in the context of HIV-related and iatrogenic immunosuppression is unlikely to 
be related to the patient’s immune function. This data adds to the evidence that FL is 
etiologically distinct from the most common NHL subtype, DLBCL. 
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Table 1. Characteristics of the adult Australian immune deficiency cohorts. 
Characteristic Kidney transplant cohort HIV cohort 
 n (%) PY (mean) n (%) PY (mean) 
Total 7 730 (100) 50 472 (6.5) 17 175 (100) 135 179 (7.9) 
Sex     
 Male 4 573 (59) 29 747 (6.5) 15 755 (92) 125 372 (8.0) 
 Female 3 157 (41) 20 725 (6.6) 1 420 (8) 9 806 (6.9) 
Age at start of follow-up1     
 16-30 1 442 (19) 11 009 (7.6) 6 100 (36) 57 822 (9.5) 
 30-39 1 560 (20) 11 020 (7.1) 6 421 (37) 49 047 (7.6) 
 40-49 1 909 (25) 12 767 (6.7) 3 044 (18) 19 938 (6.7) 
 50-59 1 928 (25) 11 420 (5.9) 1 165 (7) 6 514 (5.6) 
 60-69 859 (11) 4 172 (4.9) 377 (2) 1 684 (4.5) 
 70-80 32 (0.4) 84 (2.6) 68 (0.4) 173 (2.5) 
Calendar period2     
 1982/85-1995 4 736 (61) 22 286 (4.7) 10 181 (59) 48 271 (4.7) 
 1996-1999 4 920 (64) 14 698 (3.0) 10 281 (60) 33 031 (3.2) 
 2000-2003/04/05 5 600 (72) 13 488 (2.4) 13 277 (77) 53 877 (4.1) 
1Follow-up commences at HIV diagnosis or first transplant 
2Calendar period time dependent 
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Table 2. Standardized incidence ratios for NHL overall and the major NHL subtypes in the 
adult Australian immune deficiency cohorts. 
NHL type1 Kidney transplant cohort2 
1982-2003 
HIV cohort 
1982–2004 
 Obs (Exp) SIR 95% CI Obs (Exp) SIR 95% CI 
All NHL 117 (12.78) 9.16 7.57-10.97 661 (19.07) 34.67 32.08-37.42 
 All B-cell 72 (10.29) 6.99 5.47-8.81 383 (14.97) 25.59 23.09-28.28 
   DLBCL 60 (3.36) 17.83 13.61-22.95 325 (5.53) 58.81 52.59-65.56 
   Follicular lymphoma 2 (2.44) 0.82 0.10-2.96 5 (4.01) 1.25 0.41-2.91 
 NHL NOS 41 (1.88) 21.79 15.64-29.56 266 (3.01) 88.46 78.15-99.76 
Obs  observed 
Exp  expected 
SIR  standardized incidence ratio 
CI  confidence interval 
NHL  Non-Hodgkin lymphoma 
DLBCL  Diffuse large B-cell lymphoma 
NOS  Not otherwise specified. 
1ICD10/O-3 codes: NHL 9591, 9670-9729, 9820-9837, 9940, 9948 and 9590 if ICD10 C82-C85; B-cell NHL 
9670-9699, 9728, 9823, 9826, 9833, 9836, 9940; DLBL 9680, 9684, 9678, 9679; Follicular 9690, 9691, 9695, 
9698; NOS 9591, 9727, 9820, 9832, 9835, 9590 (if site C82-C85) 
2Only NHLs diagnosed during transplant function, either first or higher-order grafts, were counted 
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